Pharmacokinetics/Pharmacodynamics of Argatroban Injection in End-Stage Renal Disease Patients Undergoing Hemodialysis

Completed · Phase 4

Conditions studied: Kidney Failure, Chronic, Renal Disease, End-Stage

In brief

The primary goals of this investigation are to provide guidance on how to dose Argatroban in patients undergoing hemodialysis and to assess the safety and tolerability of Argatroban in hemodialysis patients. The secondary goal of the study will be to assess the adequacy of anticoagulation during hemodialysis.

Key facts

Study ID

NCT00035178

Run by

Texas Biotechnology Corporation

People needed

12

Starts

2002-05-01

Expected to finish

2002-11-01

Last updated by the study team

2005-06-24

Who can join

Age: 21 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Chicago, Section of Nephrology — Chicago, Illinois, United States
• DaVita Clinical Research — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.